--- title: "Faron bolsters late-stage push with new CTO for lead cancer immunotherapy" type: "News" locale: "en" url: "https://longbridge.com/en/news/280584550.md" description: "Faron Pharmaceuticals has appointed Heikki Jouttijärvi as Chief Technical Officer to enhance its late-stage development efforts for the cancer immunotherapy candidate, bexmarilimab. Jouttijärvi's extensive experience in biopharma manufacturing and operations is expected to strengthen Faron's capabilities as it advances bexmarilimab into a Phase IIb trial for high-risk myelodysplastic syndromes. This appointment reflects Faron's commitment to operational readiness in the competitive cancer immunotherapy market." datetime: "2026-03-26T07:35:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280584550.md) - [en](https://longbridge.com/en/news/280584550.md) - [zh-HK](https://longbridge.com/zh-HK/news/280584550.md) generator: "portal-rs" --- # Faron bolsters late-stage push with new CTO for lead cancer immunotherapy ### Claim 30% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The latest update is out from Faron Pharmaceuticals Oy ( (GB:FARN) ). Faron Pharmaceuticals has appointed Heikki Jouttijärvi as Chief Technical Officer to support its transition into late-stage development, particularly for its lead immunotherapy candidate bexmarilimab. Jouttijärvi brings extensive experience in biopharma manufacturing, supply chain and commercial operations from senior roles at Adverum Biotechnologies, Menlo Therapeutics and Santen Pharmaceutical. Management highlighted that his background with late-stage and approved drugs is expected to strengthen Faron’s capabilities as it advances bexmarilimab into a Phase IIb trial in high-risk myelodysplastic syndromes. The appointment underscores Faron’s focus on building operational and commercial readiness around its lead oncology asset as it progresses through the clinical pipeline. **More about Faron Pharmaceuticals Oy** Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancer. Its lead asset, bexmarilimab, is a macrophage-guiding investigational immunotherapy being studied across multiple oncology settings to broaden the reach and effectiveness of immuno-oncology treatments. The company targets myeloid cell function by modulating the Clever-1 receptor on macrophages, aiming to reprogram the tumor microenvironment from immunosuppressive to immunostimulatory. Listed on AIM and Nasdaq First North, Faron positions itself within the competitive cancer immunotherapy space, seeking to address resistance to current standard-of-care therapies. ### Related Stocks - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [MASTERINVEST Kapitalanlage GmbH Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/297304654.md) - [Washington Trust Bank Sells 3,603 Shares of Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/297422593.md) - [Algert Global LLC Has $6.78 Million Position in BioMarin Pharmaceutical Inc. $BMRN](https://longbridge.com/en/news/297137182.md) - [17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLC](https://longbridge.com/en/news/297394382.md) - [Clal Insurance Enterprises Holdings Ltd Buys Shares of 2,019 Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/296756674.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**